Sotac Pharma.

Why is Sotac Pharmaceuticals Ltd falling/rising?

As of 22-Jul, the stock price of Sotac Pharmaceuticals Ltd is at 95.10, unchanged from the previous day, and has declined significantly by 22.75% year-to-date. The stock is underperforming compared to the benchmark Sensex and shows a bearish trend with reduced investor participation.

As of 22-Jul, the stock price of Sotac Pharmaceuticals Ltd is currently at 95.10, with no change from the previous day. The stock has shown a significant decline over various periods, with a year-to-date drop of 22.75% and a one-year decrease of 23.31%. In contrast, the benchmark Sensex has only fallen by 8.16% year-to-date, indicating that Sotac Pharmaceuticals is underperforming relative to the market.<BR><BR>Today, the stock has outperformed its sector by 1.33%, but this is overshadowed by its overall poor performance in the longer term. The stock is trading below its moving averages across all time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 93.24% compared to the 5-day average, indicating reduced interest from investors.<BR><BR>Overall, the combination of significant declines in stock performance over multiple time frames, underperformance against the benchmark, and falling investor participation are contributing factors to the current stagnation in the stock price of Sotac Pharmaceuticals Ltd.

Which are the latest news on Sotac Pharma.?

Should I buy, sell or hold Sotac Pharmaceuticals Ltd?

What does Sotac Pharma. do?

Sotac Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 25 Cr and a net profit of 1 Cr for June 2024. Key metrics include a P/E of 26.00 and a market cap of INR 123 Cr.

Overview: <BR>Sotac Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History: <BR>Sotac Pharmaceuticals was originally formed as a Partnership Firm in 2015 and was converted to a Private Limited Company later that same year. The latest quarterly results reported net sales and profit for June 2024.<BR><BR>Financial Snapshot: <BR>Net Sales: 25 Cr (Quarterly Results - Jun 2024) <BR>Net Profit: 1 Cr (Quarterly Results - Jun 2024) <BR>Market Cap: INR 123 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.09% <BR>Debt Equity: 0.62 <BR>Return on Equity: 8.11% <BR>Price to Book: 2.08<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

How big is Sotac Pharma.?

As of 10th June, Sotac Pharmaceuticals Ltd has a market capitalization of 123.00 Cr, with net sales of 104.11 Cr and a net profit of 4.64 Cr reported in the latest four quarters.

As of 10th June, Sotac Pharmaceuticals Ltd has a market capitalization of 123.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sotac Pharmaceuticals Ltd reported net sales of 104.11 Cr and a net profit of 4.64 Cr.<BR><BR>As of March 2025, the company's shareholder's funds are valued at 53.25 Cr, while total assets amount to 123.03 Cr.

Who are in the management team of Sotac Pharma.?

The management team of Sotac Pharma includes Sharadkumar Dashrathbhai Patel (Chairman & Managing Director), Dineshkumar Babulal Gelot (Whole-time Director), Vishalkumar Devrajbhai Patel, Chetankumar Bachubhai Patel (both Executive Directors), and three Independent Non-Executive Directors: Ms. Nidhiben Patel, Hetal Umangbhai Shah, and Heena Viral Patel. They oversee the company's operations and strategic direction.

The management team of Sotac Pharma includes the following individuals:<BR><BR>1. **Sharadkumar Dashrathbhai Patel** - Chairman & Managing Director<BR>2. **Dineshkumar Babulal Gelot** - Whole-time Director<BR>3. **Vishalkumar Devrajbhai Patel** - Executive Director<BR>4. **Chetankumar Bachubhai Patel** - Executive Director<BR>5. **Ms. Nidhiben Patel** - Independent Non-Executive Director<BR>6. **Hetal Umangbhai Shah** - Independent Non-Executive Director<BR>7. **Heena Viral Patel** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Sotac Pharma.?

Sotac Pharma's peers include Balaxi Pharma, Vaishali Pharma, Godavari Drugs, and others. In terms of management risk, Sotac Pharma is rated below average, with an average growth outlook and a 1-year return of -11.66%.

Peers: The peers of Sotac Pharma are Balaxi Pharma, Vaishali Pharma, Godavari Drugs, Concord Drugs, Tyche Industries, Denis Chem Lab, Pharmaids Pharma, Lactose (India), Smruthi Organic.<BR><BR>Quality Snapshot: Excellent management risk is observed at Denis Chem Lab and Tyche Industries, while Average management risk is found at Balaxi Pharma and Smruthi Organic. Below Average management risk is seen at Sotac Pharma, Vaishali Pharma, Godavari Drugs, Concord Drugs, Pharmaids Pharma, and Lactose (India). Growth is Excellent at Lactose (India), Average at Sotac Pharma, and Below Average at Balaxi Pharma, Vaishali Pharma, Godavari Drugs, Concord Drugs, Tyche Industries, Denis Chem Lab, Pharmaids Pharma, and Smruthi Organic. Capital Structure is Excellent at Balaxi Pharma, Tyche Industries, and Denis Chem Lab, Average at Sotac Pharma, and Below Average at Vaishali Pharma, Godavari Drugs, Concord Drugs, Pharmaids Pharma, Lactose (India), and Smruthi Organic.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Godavari Drugs at 0.00%, while the peer with the lowest is Balaxi Pharma at -56.08%. Sotac Pharma's 1-year return of -11.66% is better than Balaxi Pharma's but worse than Godavari Drugs'. Additionally, Balaxi Pharma, Vaishali Pharma, and Smruthi Organic have negative six-month returns.

How has been the historical performance of Sotac Pharma.?

Sotac Pharma's historical performance shows fluctuating net sales, peaking at 103.83 Cr in March 2024 before declining to 96.99 Cr in March 2025, while profitability improved significantly with profit after tax rising to 9.28 Cr in March 2025 from 3.58 Cr in the previous year. Total assets and liabilities both increased to 123.03 Cr in March 2025, indicating growth in operations despite negative cash flow from operating activities.

Answer:<BR>The historical performance of Sotac Pharma shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Sotac Pharma's net sales peaked at 103.83 Cr in March 2024 but declined to 96.99 Cr by March 2025, following a steady increase from 28.60 Cr in March 2020 to 77.48 Cr in March 2023. Total operating income mirrored this trend, reaching 96.99 Cr in March 2025. The company's total expenditure, excluding depreciation, was 83.34 Cr in March 2025, down from 95.32 Cr in March 2024, which contributed to an operating profit of 17.55 Cr in March 2025, a significant increase from 9.00 Cr in the previous year. Profit before tax also rose to 11.12 Cr in March 2025, compared to 3.96 Cr in March 2024, leading to a profit after tax of 9.28 Cr, up from 3.58 Cr. The earnings per share improved to 7.27 in March 2025 from 3.87 in March 2024. On the balance sheet, total assets increased to 123.03 Cr in March 2025, while total liabilities also rose to 123.03 Cr, indicating a growing scale of operations. Cash flow from operating activities remained negative at -4.00 Cr in March 2025, although cash flow from financing activities was positive at 16.00 Cr, reflecting ongoing investments and financing strategies.

Is Sotac Pharma. overvalued or undervalued?

As of October 7, 2025, Sotac Pharma is fairly valued with a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, making it attractive compared to peers like Sun Pharma and Divi's Lab, despite a 13.16% decline over the past year.

As of 7 October 2025, the valuation grade for Sotac Pharma has moved from very attractive to attractive. The company is currently fairly valued. Key ratios include a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, indicating a relatively low growth expectation compared to its earnings. <BR><BR>In comparison to its peers, Sotac Pharma's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive. However, it is higher than Cipla's attractive PE of 22.68 and Dr. Reddy's Labs at 18.37, both of which suggest a more favorable valuation. Despite a recent stock return of 5% over the past week compared to the Sensex's 2.02%, the longer-term performance shows a decline of 13.16% over the past year, reinforcing the notion that the stock is currently fairly valued within its sector.

Who are the top shareholders of the Sotac Pharma.?

The top shareholders of Sotac Pharma include Kiran Baldevbhai Jotania with 13.11%, foreign institutional investors holding 15.12%, and Nav Capital Vcc - Nav Capital Emerging Star Fund as the largest public shareholder at 7.09%. Individual investors own 4.7% of the shares, with no pledged promoter holdings or mutual fund schemes.

The top shareholders of Sotac Pharma include several key players. The majority shareholders are the promoters, with Kiran Baldevbhai Jotania holding the highest stake at 13.11%. Additionally, there are three foreign institutional investors (FIIs) collectively holding 15.12% of the shares. The highest public shareholder is Nav Capital Vcc - Nav Capital Emerging Star Fund, which holds 7.09%. Individual investors account for 4.7% of the company's shares. Notably, there are no pledged promoter holdings or mutual fund schemes involved.

What is the technical trend for Sotac Pharma.?

As of May 30, 2025, Sotac Pharma shows a mildly bullish trend overall, supported by the weekly MACD and moving averages, but caution is advised due to mixed signals from the weekly RSI and OBV.

As of 30 May 2025, the technical trend for Sotac Pharma has changed from sideways to mildly bullish. The weekly MACD indicates a bullish stance, while the daily moving averages also reflect a mildly bullish outlook. However, the weekly RSI is bearish, suggesting some weakness in momentum. The Bollinger Bands on a weekly basis are mildly bullish, but the monthly view is bearish. The KST is bullish on the weekly timeframe, while the OBV shows a mildly bearish trend. Overall, the current technical stance is mildly bullish, but the mixed signals, particularly from the RSI and OBV, indicate caution.

When is the next results date for Sotac Pharma.?

No Upcoming Board Meetings

Has Sotac Pharma. declared dividend?

No Dividend History Available